

Title (en)

Pharmaceutical composition comprising lacosamide and levetiracetam with synergistic anticonvulsant effect

Title (de)

Pharmazeutische Zubereitung, enthaltend Lacosamide und Levetiracetam, mit synergistischer antikonvulsiver Wirkung

Title (fr)

Composition pharmaceutique, comprenant lacosamide et levetiracetam, ayant un effet anticonvulsivant synergique

Publication

**EP 2462990 A1 20120613 (EN)**

Application

**EP 12001535 A 20070615**

Priority

- EP 07764676 A 20070615
- US 81396706 P 20060615
- EP 06021469 A 20061012
- EP 06021470 A 20061012
- EP 06024241 A 20061122
- EP 12001535 A 20070615

Abstract (en)

The present invention is directed to a pharmaceutical composition comprising (a) lacosamide and (b) levetiracetam for the prevention, alleviation or/and treatment of epileptic seizures.

IPC 8 full level

**A61P 25/08** (2006.01); **A61K 31/165** (2006.01); **A61K 31/4015** (2006.01); **A61K 38/05** (2006.01)

CPC (source: EP KR US)

**A61K 31/165** (2013.01 - EP KR US); **A61K 31/19** (2013.01 - EP US); **A61K 31/195** (2013.01 - EP US); **A61K 31/35** (2013.01 - EP US); **A61K 31/40** (2013.01 - EP KR US); **A61K 31/4015** (2013.01 - EP US); **A61K 31/4166** (2013.01 - EP US); **A61K 31/53** (2013.01 - EP US); **A61K 31/55** (2013.01 - EP US); **A61K 38/04** (2013.01 - EP KR US); **A61K 38/05** (2013.01 - EP US); **A61K 45/06** (2013.01 - EP US); **A61P 25/00** (2017.12 - EP); **A61P 25/08** (2017.12 - EP); **A61P 25/10** (2017.12 - EP); **A61P 25/12** (2017.12 - EP); **A61P 43/00** (2017.12 - EP); **B65D 81/32** (2013.01 - US)

Citation (applicant)

- US 5378729 A 19950103 - KOHN HAROLD L [US], et al
- US 5773475 A 19980630 - KOHN HAROLD [US]
- EP 1541138 A1 20050615 - SANOL ARZNEI SCHWARZ GMBH [DE]
- EP 2005010603 W 20050930
- J. MARCH: "Advanced Organic Chemistry", 1985, JOHN WILEY AND SONS, pages: 16 - 18
- LOSCHER, W.; NOLTING, B.: "The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. IV. Protective indices", EPILEPSY RES, vol. 9, 1991, pages 1 - 10, XP024394354, DOI: doi:10.1016/0920-1211(91)90041-D
- LUSZCZKI JJ; BOROWICZ KK; SWIADER M; CZUCZWAR SJ: "Interactions between oxcarbazepine and conventional antiepileptic drugs in the maximal electroshock test in mice: an isobolographic analysis", EPILEPSIA, vol. 44, 2003, pages 489 - 99
- BARTON, M.E.; KLEIN, B.D.; WOLF, H.H.; WHITE, H.S.: "Pharmacological characterization of the 6 Hz psychomotor seizure model of partial epilepsy", EPILEPSY RES, vol. 47, 2001, pages 217 - 227, XP055090437, DOI: doi:10.1016/S0920-1211(01)00302-3
- BERENBAUM, M.C.: "What is synergy?", PHARMACOL REV, vol. 41, 1989, pages 93 - 141, XP002105789
- BIALER, M.; JOHANNESSEN, S.I.; KUPFERBERG, H.J.; LEVY, R.H.; LOISEAU, P.; PERUCCA, E.: "Progress report on new antiepileptic drugs: a summary of the Fifth Eilat Conference (EILAT V)", EPILEPSY RESEARCH, vol. 43, 2001, pages 11 - 58
- BIALER, M.; JOHANNESSEN, S.I.; KUPFERBERG, H.J.; LEVY, R.H.; LOISEAU, P.; PERUCCA, E.: "Progress report on new antiepileptic drugs: a summary of the Sixth Eilat Conference (EILAT VI)", EPILEPSY RESEARCH, vol. 51, 2002, pages 31 - 71, XP002274395, DOI: doi:10.1016/S0920-1211(02)00106-7
- BIALER, M.; JOHANNESSEN, S.I.; KUPFERBERG, H.J.; LEVY, R.H.; PERUCCA, E.; TORBJORN, T.: "Progress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference (EILAT VII)", EPILEPSY RESEARCH, vol. 61, 2004, pages 1 - 48, XP004579931, DOI: doi:10.1016/j.eplepsyres.2004.07.010
- BOROWICZ, K.K.; KLEINROK, Z.; CZUCZWAR, S.J.: "The AMPA/kainate receptor antagonist, LY 300164, increases the anticonvulsant effects of diazepam", NAUNYN SCHMIEDEBERGS ARCH PHARMACOL, vol. 361, 2000, pages 629 - 35
- BOROWICZ, K.K.; SWIADER, M.; LUSZCZKI, J.; CZUCZWAR, S.J.: "Effect of gabapentin on the anticonvulsant activity of antiepileptic drugs against electroconvulsions in mice: an isobolographic analysis", EPILEPSIA, vol. 43, 2002, pages 956 - 963
- BOURGEOIS, B.F.D.: "Anticonvulsant potency and neurotoxicity of valproate alone and in combination with carbamazepine and phenobarbital", CLIN NEUROPHARMACOL, vol. 11, 1988, pages 348 - 59
- BOURGEOIS, B.F.D.; WAD, N.: "Combined administration of carbamazepine and phenobarbital: effect on anticonvulsant activity and neurotoxicity", EPILEPSIA, vol. 29, 1988, pages 482 - 7
- BRODIE, M.J.: "Do we need any more new antiepileptic drugs?", EPILEPSY RES, vol. 45, 2001, pages 3 - 6
- DECKERS, C.L.P.; CZUCZWAR, S.J.; HEKSTER, Y.A. ET AL.: "Selection of antiepileptic drug polytherapy based on mechanisms of action: the evidence reviewed", EPILEPSIA, vol. 41, 2000, pages 1364 - 1374, XP009035157, DOI: doi:10.1111/j.1528-1157.2000.tb00111.x
- DUNHAM, N.W.; MIYA, T.S.: "A note on a simple apparatus for detecting neurological deficit in rats and mice", J. AM. PHARM. ASSOC., vol. 46, 1957, pages 208 - 209
- GOWER, A.J.; NOYER, M.; VERLOES, R. ET AL.: "Ucb L059, a novel anticonvulsant drug: pharmacological profile in animals", EUR J PHARMACOL, vol. 222, 1992, pages 193 - 203
- ERRATUM, EUR J PHARMACOL, vol. 230, 1993, pages 389
- HOVINGA, C.A.: "Erlasamide Schwarz Pharma", DRUGS, vol. 6, no. 5, 2003
- KERRY, D.W.; HAMILTON-MILLER, J.M.T.; BRUMFITT, W.: "Trimethoprim and rifampicin: in vitro activities separately and in combination", J ANTIMICROB CHEMOTHER, vol. 1, 1975, pages 417 - 27
- KLITGAARD, H.; MATAGNE, A.; GOBERT, J. ET AL.: "Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy", EUR J PHARMACOL, vol. 353, 1998, pages 191 - 206, XP000910515, DOI: doi:10.1016/S0014-2999(98)00410-5
- KRAMER, G.: "The limitations of antiepileptic drug monotherapy", EPILEPSIA, vol. 38, no. 5, 1997, pages S9 - S13
- LITCHFIELD, J.T.; WILCOXON, F.: "A simplified method of evaluating dose-effect experiments", J. PHARMACOL EXP THER, vol. 96, 1949, pages 99 - 113
- LOISEAU, P.: "DO we need novel anti-epileptic drugs?", BR. J. CLIN. PRACT., vol. 42, 1988, pages 2 - 3

- LOSCHER, W.; HONACK, D.: "Profile of ucb L059, a novel anticonvulsant drug, in models of partial and generalized epilepsy in mice and rats", EUR J PHARMACOL, vol. 232, 1993, pages 147 - 158, XP023770418, DOI: doi:10.1016/0014-2999(93)90768-D
- LOSCHER, W.; NOLTING, B.: "The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. IV. Protective indices", EPILEPSY RES, vol. 9, 1991, pages 1 - 10, XP024394354, DOI: doi:10.1016/0920-1211(91)90041-D
- LUSZCZKI, J.J.; ANDRES, M.M.; CZUCZWAR, P.; CIOCZEK-CZUCZWAR, A.; RATNARAJ, N.; PATSALOS, P.N.; CZUCZWAR S.J.: "Pharmacodynamic and pharmacokinetic characterization of interactions between Levetiracetam and numerous antiepileptic drugs in the mouse maximal electroshock seizure model: an isobolographical analysis", EPILEPSIA, vol. 47, 2006, pages 10 - 20, XP055492666
- LUSZCZKI, J.J.; CZUCZWAR, M.; KIS, J.; KRYSA, J.; PASZTELAN, I.; SWIADER, M.; CZUCZWAR, S.J.: "Interactions of lamotrigine with topiramate and first- generation antiepileptic drugs in the maximal electroshock test in mice: an isobolographic analysis", EPILEPSIA, vol. 44, no. 8, 2003, pages 1003 - 1013, XP055492662
- LUSZCZKI, J.J.; CZUCZWAR, S.J.: "Isobolographic and subthreshold methods in the detection of interactions between oxcarbazepine and conventional antiepileptics - a comparative study", EPILEPSY RES., vol. 56, 2003, pages 27 - 42
- PATSALOS, P.N.: "Levetiracetam: pharmacology and therapeutics in the treatment of epilepsy and other neurological conditions", REV CONTEMP PHARMACOTHER, vol. 13, 2004, pages 1 - 168
- PORRECA, F.; JIANG, Q.; TALLARIDA, R.J.: "Modulation of morphine antinociception by peripheral [Leu5] enkephalin: a synergistic interaction", EUR J PHARMACOL, vol. 179, 1990, pages 463 - 468
- SANDER, J.W.A.S.; SHORVON, S.D.: "Incidence and prevalence studies in epilepsy and their methodological problems: a review", J. NEUROL. NEUROSURG. PSYCHIAT., vol. 50, 1987, pages 829 - 839
- J. MARCH,.: "Intractable Epilepsy: Experimental and Clinical Aspects", 1986, RAVEN PRESS
- TALLARIDA, R.J.: "Statistical analysis of drug combinations for synergism", PAIN, vol. 49, 1992, pages 93 - 7, XP024379838, DOI: doi:10.1016/0304-3959(92)90193-F
- TALLARIDA, R.J.; STONE, D.J.; MCCARY, J.D. ET AL.: "Response surface analysis of synergism between morphine and clonidine", J PHARMACOL EXP THER, vol. 289, 1999, pages 8 - 13
- TALLARIDA, R.J.; STONE, D.J.; RAFFA, R.B.: "Efficient designs for studying synergistic drug combinations", LIFE SCI, vol. 61, 1997, pages PL417 - 25
- TALLARIDA, R.J.: "The interaction index: a measure of drug synergism", PAIN, vol. 98, 2002, pages 163 - 8, XP055071866, DOI: doi:10.1016/S0304-3959(02)00041-6
- WARNER, T.; PATSALOS, P.N.; PREVETT, M. ET AL.: "Lamotrigine-induced carbamazepine toxicity: an interaction with carbamazepine-10,11-epoxide", EPILEPSY RES, vol. 11, 1992, pages 147 - 50, XP024394370, DOI: doi:10.1016/0920-1211(92)90049-Y

#### Citation (search report)

- [Y] HOVINGA C A: "SPM-927", IDRUGS, CURRENT DRUGS LTD, GB, vol. 6, no. 5, May 2003 (2003-05-01), pages 479 - 485, XP001180322, ISSN: 1369-7056
- [Y] DUNCAN G E ET AL: "The novel antiepileptic drug lacosamide blocks behavioral and brain metabolic manifestations of seizure activity in the 6Hz psychomotor seizure model", EPILEPSY RESEARCH, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 67, no. 1-2, 1 October 2005 (2005-10-01), pages 81 - 87, XP025354904, ISSN: 0920-1211, [retrieved on 20051001]
- [Y] BERAN R G ET AL: "Efficacy and safety of levetiracetam 1000-3000mg/day in patients with refractory partial-onset seizures: a multicenter, open-label single-arm study", EPILEPSY RESEARCH, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 63, no. 1, 1 January 2005 (2005-01-01), pages 1 - 9, XP027832669, ISSN: 0920-1211, [retrieved on 20050101]
- [Y] OLIVEIRA A A ET AL: "Evaluation of levetiracetam effects on pilocarpine-induced seizures: Cholinergic muscarinic system involvement", NEUROSCIENCE LETTERS, LIMERICK, IE, vol. 385, no. 3, 16 September 2005 (2005-09-16), pages 184 - 188, XP004979098, ISSN: 0304-3940, DOI: 10.1016/J.NEULET.2005.05.048
- [Y] CEREGHINO J J ET AL: "LEVETIRACETAM FOR PARTIAL SEIZURES RESULTS OF A DOUBLE-BLIND, RANDOMIZED CLINICAL TRIAL", NEUROLOGY, LIPPINCOTT WILLIAMS & WILKINS, PHILADELPHIA, US, vol. 55, no. 2, 25 July 2000 (2000-07-25), pages 236 - 242, XP001026757, ISSN: 0028-3878, DOI: 10.1159/00006657

#### Cited by

EP2878296A1; US11369606B2; WO2015079010A3; WO2015110435A1; US10537573B2; US11103506B2; KR20160108359A; EP3424535A1; EP3431106A1; AU2015208233B2; EA033889B1; AU2019208181B2; EP3827830A1; AU2020286271B2; AU2021200512B2; AU2020286269B2

#### Designated contracting state (EPC)

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

#### DOCDB simple family (publication)

**US 2010240576 A1 20100923; US 8735356 B2 20140527;** AR 061476 A1 20080827; AU 2007260207 A1 20071221; AU 2007260207 B2 20121108; BR PI0713594 A2 20121030; CA 2651679 A1 20071221; CA 2651679 C 20170103; CN 102846601 A 20130102; CN 102846601 B 20150429; CY 1114920 T1 20161214; DK 2462990 T3 20140217; EA 019757 B1 20140630; EA 027836 B1 20170929; EA 200900020 A1 20090630; EA 201300702 A1 20131030; EP 2037965 A2 20090325; EP 2037965 B1 20170830; EP 2462990 A1 20120613; EP 2462990 B1 20140101; EP 2462990 B2 20180418; EP 2695618 A1 20140212; EP 2695618 B1 20140924; EP 2695618 B2 20220511; EP 2992891 A1 20160309; EP 2992891 B1 20200805; ES 2450070 T3 20140321; ES 2450070 T5 20180508; ES 2531118 T3 20150310; ES 2531118 T5 20220614; ES 2645529 T3 20171205; ES 2822904 T3 20210505; JP 2009545521 A 20091224; JP 2013237705 A 20131128; JP 2016104808 A 20160609; JP 5443981 B2 20140319; JP 5898149 B2 20160406; JP 6158376 B2 20170705; KR 101518427 B1 20150508; KR 20090030308 A 20090324; KR 20150003925 A 20150109; MX 2008016000 A 20090305; PL 2462990 T3 20140530; PT 2462990 E 20140402; SI 2462990 T1 20140430; TW 200812568 A 20080316; TW I397417 B 20130601; US 2012238614 A1 20120920; US 2014088168 A1 20140327; US 2015202184 A1 20150723; US 8828943 B2 20140909; US 9095557 B2 20150804; US 9446011 B2 20160920; WO 2007144195 A2 20071221; WO 2007144195 A3 20080904

#### DOCDB simple family (application)

**US 30402307 A 20070615;** AR P070102636 A 20070615; AU 2007260207 A 20070615; BR PI0713594 A 20070615; CA 2651679 A 20070615; CN 201210334137 A 20070615; CY 141100167 T 20140228; DK 12001535 T 20070615; EA 200900020 A 20070615; EA 201300702 A 20070615; EP 07764676 A 20070615; EP 12001535 A 20070615; EP 13004798 A 20070615; EP 15156237 A 20070615; EP 2007005304 W 20070615; ES 07764676 T 20070615; ES 12001535 T 20070615; ES 13004798 T 20070615; ES 15156237 T 20070615; JP 2009514711 A 20070615; JP 2013180975 A 20130902; JP 2016031870 A 20160223; KR 20097000805 A 20090114; KR 20147035732 A 20070615; MX 2008016000 A 20070615; PL 12001535 T 20070615; PT 12001535 T 20070615; SI 200731422 T 20070615; TW 96121853 A 20070615; US 201213428419 A 20120323; US 201314080440 A 20131114; US 201514674418 A 20150331